metopimazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1784 14008-44-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metopimazine hydrochloride
  • metopimazine HCl
  • metopimazine
  • vogalene
  • Molecular weight: 445.60
  • Formula: C22H27N3O3S2
  • CLOGP: 1.30
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 83.71
  • ALOGS: -4.37
  • ROTB: 6

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance) 12.14 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.383 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 20.654 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 3.548 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 10.568 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 21.320 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 36.370 % High 1
herg hERG pIC50 5.621 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 7.413 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 21.184 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 20.600 % High 1
kinase-safety-class ACVR2B,AKT2,AKT3,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MARK4,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK 36
kinase-selectivity-class AXL,MAP2K6,PDK4,SIK2,STK33,TEK 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 13.677 High 1
mh-clint Mouse hepatocyte intrinsic clearance 58.479 High 1
mppb Mouse plasma protein binding (% unbound) 22.150 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 27.925 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 37.820 % High 1
rh-clint Rat hepatocyte intrinsic clearance 48.195 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 61.970 % High 1
rppb Rat plasma protein binding (% unbound) 19.670 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 421.697 uM High 1

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 114.34 40.09 73 1685 320314 90306375
Pancreatitis acute 83.23 40.09 29 1729 32086 90594603
Hyperkalaemia 63.43 40.09 29 1729 64935 90561754
Ischaemic stroke 61.21 40.09 21 1737 22145 90604544
Cholestasis 54.55 40.09 22 1736 36277 90590412
Hepatic cytolysis 50.85 40.09 20 1738 30896 90595793
Drug reaction with eosinophilia and systemic symptoms 47.81 40.09 21 1737 42737 90583952
Febrile bone marrow aplasia 46.52 40.09 14 1744 9724 90616965
Lactic acidosis 41.42 40.09 20 1738 50443 90576246

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 132.53 34.68 117 2698 635313 109951171
Pancreatitis acute 108.91 34.68 45 2770 60229 110526255
Coma 69.47 34.68 41 2774 117828 110468656
Hepatic cytolysis 63.46 34.68 30 2785 55023 110531461
Cholestasis 56.04 34.68 29 2786 64489 110521995
Poisoning deliberate 55.56 34.68 22 2793 26309 110560175
Analgesic drug level increased 55.26 34.68 14 2801 3932 110582552
Rash maculo-papular 54.98 34.68 30 2785 74192 110512292
Hyperkalaemia 52.00 34.68 36 2779 135760 110450724
Drug reaction with eosinophilia and systemic symptoms 49.50 34.68 29 2786 82066 110504418
Ischaemic stroke 49.12 34.68 23 2792 41240 110545244
Intestinal transit time decreased 46.56 34.68 7 2808 124 110586360
Lactic acidosis 43.71 34.68 28 2787 92783 110493701
Thrombocytopenia 42.15 34.68 48 2767 348837 110237647
Febrile bone marrow aplasia 41.82 34.68 16 2799 17449 110569035
Altered state of consciousness 39.12 34.68 22 2793 57604 110528880
Hepatocellular injury 36.19 34.68 20 2795 50622 110535862

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A04AD05 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:50919 antiemetic

Related Drugs by ATC class:

A04AD Other antiemetics 8 drugs
aprepitantcasopitantcerium oxalatechlorobutanoldronabinolnabilonerolapitantscopolamine

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.41 acidic
pKa2 8.95 Basic
pKa3 3.45 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR Ki 10.15 CHEMBL
D(3) dopamine receptor GPCR Ki 9.21 CHEMBL
Histamine H1 receptor GPCR Ki 8.08 CHEMBL

External reference:

IDSource
D05010 KEGG_DRUG
C0066469 UMLSCUI
CHEBI:135726 CHEBI
CHEMBL398615 ChEMBL_ID
DB13591 DRUGBANK_ID
C005260 MESH_SUPPLEMENTAL_RECORD_UI
11140 IUPHAR_LIGAND_ID
2178 INN_ID
238S75V9AV UNII
26388 PUBCHEM_CID
29954 RXNORM
005826 NDDF

Pharmaceutical products:

None